Biotech Playbook Breakdown Who Will Risk Developing Tomorrow's Cures

The biotechnology industry's traditional division of risk among academia, venture capital, and pharmaceutical companies is shifting, with investors increasingly favouring biotech firms that have already de-risked their drug candidates before funding. This change impacts early-stage biotech investments and the development of transformative therapies like regenerative medicine, which face new challenges in manufacturing, regulation, and commercialisation.

This Wire brief sits within Fusion42's coverage of Biotech.